Effect of IL-17 receptor A blockade with brodalumab in inflammatory diseases

Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials

(2015) Christopher E M Griffiths et al.   LANCET

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Human IL-17F/IL-17A Heterodimeric Cytokine Signals through the IL-17RA/IL-17RC Receptor Complex

(2014) J. F. Wright et al.   JOURNAL OF IMMUNOLOGY

Identification of Functional Roles for Both IL-17RB and IL-17RA in Mediating IL-25-Induced Activities

(2014) E. A. Rickel et al.   JOURNAL OF IMMUNOLOGY

TH17 Cells Mediate Steroid-Resistant Airway Inflammation and Airway Hyperresponsiveness in Mice

(2014) L. McKinley et al.   JOURNAL OF IMMUNOLOGY

Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody

(2014) C. B. Russell et al.   JOURNAL OF IMMUNOLOGY

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

(2014) Philip J. Mease et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

The anti-IL-17A antibody secukinumab does not attenuate ozone-induced airway neutrophilia in healthy volunteers

(2013) A. Kirsten et al.   EUROPEAN RESPIRATORY JOURNAL

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab (AMG 827) in Subjects with Moderate to Severe Asthma

(2013) William W. Busse et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

Cross-Study Homogeneity of Psoriasis Gene Expression in Skin across a Large Expression Range

(2013) Jeannette Bigler et al.   PLoS One

Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study

(2012) Mark C Genovese et al.   ANNALS OF THE RHEUMATIC DISEASES

Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomised, double-blind, placebo-controlled, phase II regimen-finding study

(2012) P. Rich et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study

(2012) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Mo2083 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Moderate to Severe Crohn's Disease

(2012) Stephan R. Targan et al.   GASTROENTEROLOGY

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis

(2012) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Autocrine-regulated airway smooth muscle cell migration is dependent on IL-17–induced growth-related oncogenes

(2012) Laila A. Al-Alwan et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-17 and TNF-  Sustain Neutrophil Recruitment during Inflammation through Synergistic Effects on Endothelial Activation

(2012) G. K. Griffin et al.   JOURNAL OF IMMUNOLOGY

Anti-IL-17 Receptor Antibody AMG 827 Leads to Rapid Clinical Response in Subjects with Moderate to Severe Psoriasis: Results from a Phase I, Randomized, Placebo-Controlled Trial

(2012) Kim A. Papp et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

IL-17A produced by αβ T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction

(2012) Makoto Kudo et al.   NATURE MEDICINE

Interleukin-25 induces type 2 cytokine production in a steroid-resistant interleukin-17RB+ myeloid population that exacerbates asthmatic pathology

(2012) Bryan C Petersen et al.   NATURE MEDICINE

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

(2012) Craig Leonardi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interleukin-17C Promotes Th17 Cell Responses and Autoimmune Disease via Interleukin-17 Receptor E

(2011) Seon Hee Chang et al.   IMMUNITY

Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis

(2011) A. M. Lin et al.   JOURNAL OF IMMUNOLOGY

Spondyloarthritis

(2011) Maxime Dougados et al.   LANCET

Control of TH17 cells occurs in the small intestine

(2011) Enric Esplugues et al.   NATURE

IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens

(2011) Xinyang Song et al.   NATURE IMMUNOLOGY

Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)

(2011) Dongxu Sun et al.   NATURE IMMUNOLOGY

IL-17C regulates the innate immune function of epithelial cells in an autocrine manner

(2011) Vladimir Ramirez-Carrozzi et al.   NATURE IMMUNOLOGY

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

(2010) M. C. Genovese et al.   ARTHRITIS AND RHEUMATISM

The increased mucosal mRNA expressions of complement C3 and interleukin-17 in inflammatory bowel disease

(2010) T. Sugihara et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Genetic variations associated with psoriasis and psoriatic arthritis found by genome-wide association

(2010) Kristina Callis Duffin et al.   Dermatologic Therapy

The IL-17 Family Cytokines in Immunity and Disease

(2010) Rajita Pappu et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1 , and TNF-  Recapitulates Some Features of Psoriasis

(2010) K. Guilloteau et al.   JOURNAL OF IMMUNOLOGY

Critical Role of IL-25 in Nematode Infection-Induced Alterations in Intestinal Function

(2010) A. Zhao et al.   JOURNAL OF IMMUNOLOGY

IL-1RL2 and Its Ligands Contribute to the Cytokine Network in Psoriasis

(2010) H. Blumberg et al.   JOURNAL OF IMMUNOLOGY

Assessment of the Psoriatic Transcriptome in a Large Sample: Additional Regulated Genes and Comparisons with In Vitro Models

(2010) Johann E. Gudjonsson et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Integrative Responses to IL-17 and TNF-α in Human Keratinocytes Account for Key Inflammatory Pathogenic Circuits in Psoriasis

(2010) Andrea Chiricozzi et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2

(2010) Eva Ellinghaus et al.   NATURE GENETICS

Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis

(2010) Ulrike Hüffmeier et al.   NATURE GENETICS

Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma

(2010) Stephane Lajoie et al.   NATURE IMMUNOLOGY

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

(2010) W. Hueber et al.   Science Translational Medicine

Diverse Genome-wide Association Studies Associate the IL12/IL23 Pathway with Crohn Disease

(2009) Kai Wang et al.   AMERICAN JOURNAL OF HUMAN GENETICS

Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis

(2009) J T Elder   GENES AND IMMUNITY

Differential Roles of Interleukin-17A and -17F in Host Defense against Mucoepithelial Bacterial Infection and Allergic Responses

(2009) Harumichi Ishigame et al.   IMMUNITY

TH17-associated cytokines (IL-17A and IL-17F) in severe asthma

(2009) Wisam Al-Ramli et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes

(2009) Lisa C. Zaba et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-17 Regulates CXCL1 mRNA Stability via an AUUUA/Tristetraprolin-Independent Sequence

(2009) S. Datta et al.   JOURNAL OF IMMUNOLOGY

Genome-wide scan reveals association of psoriasis with IL-23 and NF-κB pathways

(2009) Rajan P Nair et al.   NATURE GENETICS

Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides

(2008) Camilla Jandus et al.   ARTHRITIS AND RHEUMATISM

Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways

(2008) K.E. Nograles et al.   BRITISH JOURNAL OF DERMATOLOGY

T Helper 17 Lineage Differentiation Is Programmed by Orphan Nuclear Receptors RORα and RORγ

(2008) Xuexian O. Yang et al.   IMMUNITY

Regulation of inflammatory responses by IL-17F

(2008) Xuexian O. Yang et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Guidelines of care for the management of psoriasis and psoriatic arthritis

(2008) Alice Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease

(2008) Jeffrey C Barrett et al.   NATURE GENETICS

Type I Interferon: Potential Therapeutic Target for Psoriasis?

(2008) Yihong Yao et al.   PLoS One